Rajmohan Murali Mbbs,, Frcpa

List of Publications by Year
in descending order

195 papers	13,324 citations	22153 59 h-index	24982 109 g-index
199 all docs	199 docs citations	199 times ranked	17725 citing authors

#	Article	IF	Citations
1	Cytologic features of sex cordâ€stromal tumors in women. Cancer Cytopathology, 2022, 130, 55-71.	2.4	5
2	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. Modern Pathology, 2022, 35, 117-127.	5.5	16
3	TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. European Journal of Cancer, 2022, 161, 99-107.	2.8	10
4	Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. International Journal of Gynecological Cancer, 2022, , ijgc-2022-003430.	2.5	5
5	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. Clinical Cancer Research, 2022, 28, 4947-4956.	7.0	22
6	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. Molecular Oncology, 2021, 15, 1024-1039.	4.6	21
7	Cytologic features of undifferentiated and dedifferentiated carcinomas of the endometrium. Cancer Cytopathology, 2021, 129, 121-131.	2.4	3
8	Massively parallel sequencing analysis of 68 gastric-type cervical adenocarcinomas reveals mutations in cell cycle-related genes and potentially targetable mutations. Modern Pathology, 2021, 34, 1213-1225.	5.5	28
9	Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas. Clinical Cancer Research, 2021, 27, 2613-2623.	7.0	49
10	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
11	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. Gynecologic Oncology, 2021, 161, 535-544.	1.4	16
12	Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology. European Journal of Cancer, 2021, 148, 340-347.	2.8	5
13	Characterization, isolation, and in vitro culture of leptomeningeal fibroblasts. Journal of Neuroimmunology, 2021, 361, 577727.	2.3	5
14	Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. American Journal of Surgical Pathology, 2021, 45, 77-92.	3.7	30
15	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. European Journal of Cancer, 2021, 159, 113-124.	2.8	13
16	Positron Lymphography via Intracervical ¹⁸F-FDG Injection for Presurgical Lymphatic Mapping in Cervical and Endometrial Malignancies. Journal of Nuclear Medicine, 2020, 61, 1123-1130.	5.0	8
17	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research, 2020, 26, 3881-3888.	7.0	59
18	Molecular Pathology and Genomics of Melanoma. , 2020, , 381-422.		1

#	Article	IF	Citations
19	TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response. Blood, 2020, 136, 21-23.	1.4	1
20	Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens. International Journal of Gynecological Pathology, 2019, 38, 263-275.	1.4	18
21	Clinical and genetic analysis of melanomas arising in acral sites. European Journal of Cancer, 2019, 119, 66-76.	2.8	34
22	Cytologic features of upper gynecologic tract adenocarcinomas exhibiting mesonephricâ€like differentiation. Cancer Cytopathology, 2019, 127, 521-528.	2.4	20
23	Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi. Cancers, 2019, 11, 546.	3.7	8
24	A pragmatic approach to carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology Reports, 2019, 27, 74.	0.6	0
25	High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. International Journal of Gynecological Pathology, 2019, 38, S40-S63.	1.4	164
26	PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features. American Journal of Surgical Pathology, 2019, 43, 810-818.	3.7	28
27	Somatic genetic alterations in synchronous and metachronous lowâ€grade serous tumours and highâ€grade carcinomas of the adnexa. Histopathology, 2019, 74, 638-650.	2.9	11
28	Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. Gynecologic Oncology, 2019, 152, 38-45.	1.4	18
29	Molecular Pathology and Genomics of Melanoma. , 2019, , 1-42.		2
30	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Reports, 2018, 22, 2455-2468.	6.4	75
31	Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 201-209.	4.9	75
32	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	27.8	572
33	A guided tour of selected issues pertaining to metastatic carcinomas involving or originating from the gynecologic tract. Seminars in Diagnostic Pathology, 2018, 35, 95-107.	1.5	2
34	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 680-688.	2.5	2
35	Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles. Modern Pathology, 2018, 31, 418-428.	5.5	75
36	The roles of pathology in targeted therapy of women with gynecologic cancers. Gynecologic Oncology, 2018, 148, 213-221.	1.4	24

#	Article	IF	Citations
37	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Modern Pathology, 2018, 31, 674-684.	5.5	130
38	Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	6.3	164
39	Re: van Poppelen etÂal.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912). Ophthalmology, 2018, 125, e78-e79.	5.2	3
40	<scp>BRAF^V</scp>^{600E} mutations and immunohistochemical expression of <scp>VE</scp>1 protein in lowâ€grade serous neoplasms of the ovary. Histopathology, 2018, 73, 438-443.	2.9	22
41	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	7.0	100
42	Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. Clinical Cancer Research, 2018, 24, 4494-4504.	7.0	28
43	Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. ELife, 2018, 7, .	6.0	217
44	SF3B1 and BAP1 mutations in blue nevus-like melanoma. Modern Pathology, 2017, 30, 928-939.	5.5	81
45	Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. Histopathology, 2017, 71, 480-487.	2.9	2
46	Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. Journal of Investigative Dermatology, 2017, 137, 2033-2035.	0.7	24
47	Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi. Modern Pathology, 2017, 30, 350-356.	5.5	56
48	Deletion of 3p13-14 locus spanning FOXP1 to SHQ1 cooperates with PTEN loss in prostate oncogenesis. Nature Communications, 2017, 8, 1081.	12.8	16
49	Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clinical Cancer Research, 2017, 23, 6708-6720.	7.0	194
50	Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma. , 2017, 58, 3464.		38
51	Abstract 1537: 3p13-14FOXP1-SHQ1deletion spanning multiple potential tumor suppressor genes cooperates withPTENloss in cancer. , 2017, , .		0
52	Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. American Journal of Surgical Pathology, 2016, 40, 302-312.	3.7	61
53	Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation Signature. Journal of Investigative Dermatology, 2016, 136, 1526-1528.	0.7	9
54	Squamous precursor lesions of the vulva: current classification and diagnostic challenges. Pathology, 2016, 48, 291-302.	0.6	146

#	Article	IF	Citations
55	Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology, 2016, 48, 113-131.	0.6	145
56	RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers. European Journal of Cancer, 2016, 64, 149-158.	2.8	8
57	Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system. Journal of Neuro-Oncology, 2016, 127, 435-444.	2.9	55
58	Secondary Involvement of the Adnexa and Uterine Corpus by Carcinomas of the Uterine Cervix. International Journal of Gynecological Pathology, 2015, 34, 551-563.	1.4	52
59	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget, 2015, 6, 36041-36052.	1.8	103
60	TFE3 Translocationâ€“associated Perivascular Epithelioid Cell Neoplasm (PEComa) of the Gynecologic Tract. American Journal of Surgical Pathology, 2015, 39, 394-404.	3.7	140
61	Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecologic Oncology, 2015, 138, 566-572.	1.4	34
62	Response. Journal of the National Cancer Institute, 2015, 107, djv051-djv051.	6.3	0
63	Perivascular epithelioid tumours (PEComas) of the gynaecological tract. Journal of Clinical Pathology, 2015, 68, 418-426.	2.0	75
64	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature, 2015, 526, 453-457.	27.8	191
65	Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. Cancer Immunology Research, 2015, 3, 849-854.	3.4	32
66	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nature Genetics, 2015, 47, 1194-1199.	21.4	221
67	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 10995-11000.	7.1	146
68	Analysis of SDHD promoter mutations in various types of melanoma. Oncotarget, 2015, 6, 25868-25882.	1.8	9
69	Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget, 2015, 6, 44551-44562.	1.8	37
70	Copy number alteration burden predicts prostate cancer relapse. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11139-11144.	7.1	299
71	Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Modern Pathology, 2014, 27, 175-183.	5.5	78
72	Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nature Communications, 2014, 5, 3116.	12.8	521

#	Article	IF	Citations
73	Approach to Lung Biopsies From Patients With Pneumothorax. Archives of Pathology and Laboratory Medicine, 2014, 138, 257-265.	2.5	11
74	Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. Pathology, 2014, 46, 610-616.	0.6	55
75	TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Modern Pathology, 2014, 27, 502-508.	5.5	108
76	Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects. Journal of the National Cancer Institute, 2014, 106, djt435-djt435.	6.3	64
77	MAGI-2 scaffold protein is critical for kidney barrier function. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 14876-14881.	7.1	38
78	Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Human Molecular Genetics, 2014, 23, 226-238.	2.9	96
79	DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 2014, 16, 1499-1509.	1.2	65
80	TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. Journal of the National Cancer Institute, 2014, 106, .	6.3	204
81	The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients. European Journal of Cancer, 2014, 50, 111-120.	2.8	127
82	Classification of endometrial carcinoma: more than two types. Lancet Oncology, The, 2014, 15, e268-e278.	10.7	479
83	Female germ cell tumors (GCT): The Memorial Sloan Kettering Cancer Center (MSKCC) experience.. Journal of Clinical Oncology, 2014, 32, 5539-5539.	1.6	1
84	Melanocytic Proliferations of the Eye. , 2014, , 509-527.		0
85	Melanocytic Neoplasms of the Mucosa. , 2014, , 489-508.		0
86	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nature Genetics, 2013, 45, 1226-1231.	21.4	270
87	Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell, 2013, 155, 1309-1322.	28.9	801
88	Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier. Familial Cancer, 2013, 12, 125-127.	1.9	3
89	Completion lymph node dissection in melanoma patients with positive sentinel lymph nodes. European Journal of Surgical Oncology, 2013, 39, 1164-1165.	1.0	2
90	Pathology and genetics of uveal melanoma. Pathology, 2013, 45, 18-27.	0.6	31

#	Article	IF	Citations
91	BAP1 expression in cutaneous melanoma: a pilot study. Pathology, 2013, 45, 606-609.	0.6	30
92	Tumours associated with BAP1 mutations. Pathology, 2013, 45, 116-126.	0.6	242
93	Multiple primary cutaneous melanomas: recent studies highlight features associated with more indolent behaviour. Pathology, 2013, 45, 1-3.	0.6	2
94	BAP1 protein loss by immunohistochemistry: A potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology, 2013, 45, 651-656.	0.6	71
95	Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. Pathology, 2013, 45, 55-61.	0.6	15
96	Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. Clinical Cancer Research, 2013, 19, 3143-3152.	7.0	187
97	Assessment of SLX4 Mutations in Hereditary Breast Cancers. PLoS ONE, 2013, 8, e66961.	2.5	37
98	TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma. PLoS ONE, 2013, 8, e80354.	2.5	78
99	Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma. Journal of Clinical Oncology, 2012, 30, 2678-2683.	1.6	691
100	Histological and genetic evidence for a variant of superficial spreading melanoma composed predominantly of large nests. Modern Pathology, 2012, 25, 838-845.	5.5	41
101	Toward an Improved Definition of the Tumor Spectrum Associated With BAP1 Germline Mutations. Journal of Clinical Oncology, 2012, 30, e337-e340.	1.6	99
102	Prognostic Importance of the Extent of Ulceration in Patients With Clinically Localized Cutaneous Melanoma. Annals of Surgery, 2012, 255, 1165-1170.	4.2	62
103	Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. Annals of Surgery, 2012, 255, 128-133.	4.2	103
104	A Distinct Subset of Atypical Spitz Tumors is Characterized by BRAF Mutation and Loss of BAP1 Expression. American Journal of Surgical Pathology, 2012, 36, 818-830.	3.7	264
105	Increasing Tumor Thickness is Associated with Recurrence and Poorer Survival in Patients with Merkel Cell Carcinoma. Annals of Surgical Oncology, 2012, 19, 3325-3334.	1.5	59
106	Can We Better Identify Thin Cutaneous Melanomas That are Likely to Metastasize and Cause Death?. Annals of Surgical Oncology, 2012, 19, 3310-3312.	1.5	7
107	Cutaneous Head and Neck Squamous Cell Carcinoma with Regional Metastases: The Prognostic Importance of Soft Tissue Metastases and Extranodal Spread. Annals of Surgical Oncology, 2012, 19, 274-279.	1.5	57
108	Clinicopathologic Features of Incident and Subsequent Tumors in Patients with Multiple Primary Cutaneous Melanomas. Annals of Surgical Oncology, 2012, 19, 1024-1033.	1.5	45

#	Article	IF	Citations
109	Rare De Novo Germline Copy-Number Variation in Testicular Cancer. American Journal of Human Genetics, 2012, 91, 379-383.	6.2	21
110	Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Design, Development and Therapy, 2012, 6, 391.	4.3	102
111	Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer, 2012, 118, 4519-4529.	4.1	29
112	Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 2012, 61, 702-710.	2.9	29
113	Aberrant hypermethylation in primary tumours and sentinel lymph node metastases in paediatric patients with cutaneous melanoma. British Journal of Dermatology, 2012, 166, 1319-1326.	1.5	8
114	Sentinel Lymph Nodes Containing Very Small (<0.1Âmm) Deposits of Metastatic Melanoma Cannot Be Safely Regarded as Tumor-Negative. Annals of Surgical Oncology, 2012, 19, 1089-1099.	1.5	45
115	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. Annals of Surgical Oncology, 2012, 19, 1782-1789.	1.5	30
116	GNAQ and GNA11 mutations in melanocytomas of the central nervous system. Acta Neuropathologica, 2012, 123, 457-459.	7.7	60
117	Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics, 2011, 43, 1018-1021.	21.4	662
118	Cancerâ€“testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. European Journal of Cancer, 2011, 47, 460-469.	2.8	49
119	BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell and Melanoma Research, 2011, 24, 345-351.	3.3	180
120	Concurrent involvement of thyroid gland by Wegenerâ€™s granulomatosis and papillary thyroid carcinoma. Pathology, 2011, 43, 381-383.	0.6	4
121	Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients. Annals of Surgery, 2011, 253, 1155-1164.	4.2	34
122	Assessment of Copy Number Status of Chromosomes 6 and 11 by FISH Provides Independent Prognostic Information in Primary Melanoma. American Journal of Surgical Pathology, 2011, 35, 1146-1150.	3.7	60
123	Genetic alterations in uveal melanoma. Expert Review of Ophthalmology, 2011, 6, 129-132.	0.6	0
124	Outcome of cervical intraepithelial neoplasia 2 diagnosed by punch biopsy in 131 women. Journal of Obstetrics and Gynaecology Research, 2011, 37, 754-761.	1.3	6
125	Clinical and pathological features of metastases of primary cutaneous desmoplastic melanoma. Histopathology, 2011, 58, 886-895.	2.9	19
126	The prognostic and staging implications of bone invasion in oral squamous cell carcinoma. Cancer, 2011, 117, 4460-4467.	4.1	95

#	Article	IF	Citations
127	Reply to I. Satzger et al. Journal of Clinical Oncology, 2011, 29, e316-e317.	1.6	0
128	Cytologic Features of Epithelioid Hemangioendothelioma. American Journal of Clinical Pathology, 2011, 136, 739-746.	0.7	52
129	Location of Melanoma Metastases in Sentinel Lymph Nodes: What are the Implications for Histologic Processing of Sentinel Lymph Nodes in Routine Practice?. American Journal of Surgical Pathology, 2010, 34, 127-129.	3.7	5
130	Can Histologic Parameters of Melanoma Metastases in Sentinel Lymph Nodes Reliably Select Patients Who Can Be Safely Spared Completion Lymph Node Dissection?. Annals of Surgery, 2010, 251, 1188-1189.	4.2	1
131	Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2010, 17, 138-143.	1.5	68
132	The Prognostic Value of Tumor Mitotic Rate and Other Clinicopathologic Factors in Patients with Locoregional Recurrences of Melanoma. Annals of Surgical Oncology, 2010, 17, 2992-2999.	1.5	9
133	Atypical fibroxanthoma: differential diagnosis from other sarcomatoid skin lesions. Diagnostic Histopathology, 2010, 16, 401-408.	0.4	6
134	MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 2010, 10, 497.	2.6	49
135	Prognostic factors in cutaneous desmoplastic melanoma. Cancer, 2010, 116, 4130-4138.	4.1	109
136	Melanoma exhibiting cartilaginous differentiation. Histopathology, 2010, 56, 815-821.	2.9	11
137	Pigmented epithelioid melanocytoma: a recently described melanocytic tumour of low malignant potential. Pathology, 2010, 42, 284-286.	0.6	15
138	Cytological features of transitional cell metaplasia of the lower female genital tract. Pathology, 2010, 42, 113-118.	0.6	4
139	Papillary tumour of the pineal region: cytological features and implications for intraoperative diagnosis. Pathology, 2010, 42, 474-479.	0.6	11
140	Cutaneous Metastases. , 2010, , 637-650.		2
141	Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls. Melanoma Research, 2010, 20, 203-211.	1.2	8
142	Tumor-infiltrating lymphocytes and mitotic index in metastatic melanoma as predictors of patient survival. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, E46; author reply E47.	7.1	4
143	The Pleura in Health and Disease. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 649-673.	2.1	17
144	Non-Sentinel Node Risk Score (N-SNORE): A Scoring System for Accurately Stratifying Risk of Non-Sentinel Node Positivity in Patients With Cutaneous Melanoma With Positive Sentinel Lymph Nodes. Journal of Clinical Oncology, 2010, 28, 4441-4449.	1.6	111

#	Article	IF	Citations
145	Lymphoma occurring in patients with cutaneous melanoma. Journal of Clinical Pathology, 2010, 63, 777-781.	2.0	13
146	Melanotic schwannoma mimicking metastatic pigmented melanoma: a pitfall in cytological diagnosis. Pathology, 2010, 42, 287-289.	0.6	13
147	Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Modern Pathology, 2010, 23, 45-53.	5.5	68
148	High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell and Melanoma Research, 2010, 23, 137-140.	3.3	21
149	Fine-needle biopsy of metastatic melanoma: clinical use and new applications. Lancet Oncology, The, 2010, 11, 391-400.	10.7	20
150	Histologically Ambiguous (â€œBorderlineâ€) Primary Cutaneous Melanocytic Tumors: Approaches to Patient Management Including the Roles of Molecular Testing and Sentinel Lymph Node Biopsy. Archives of Pathology and Laboratory Medicine, 2010, 134, 1770-1777.	2.5	47
151	Cytological features of melanoma in exfoliative fluid specimens. Journal of Clinical Pathology, 2009, 62, 638-643.	2.0	9
152	Outcomes following parotidectomy for metastatic squamous cell carcinoma with microscopic residual disease: Implications for facial nerve preservation. Head and Neck, 2009, 31, 21-27.	2.0	35
153	Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes. Cancer, 2009, 115, 5026-5037.	4.1	75
154	Soâ€called â€œmalignant blue nevusâ€. Cancer, 2009, 115, 2949-2955.	4.1	66
155	Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene, 2009, 28, 3058-3068.	5.9	62
156	Usefulness of smears in intraâ€operative diagnosis of newly described entities of CNS. Neuropathology, 2009, 29, 641-648.	1.2	21
157	MALIGNANT OPTIC GLIOMA PRESENTING AS AN ACUTE ANTERIOR OPTIC NEUROPATHY. Retinal Cases and Brief Reports, 2009, 3, 156-160.	0.6	4
158	Pigmented Epithelioid Melanocytoma: Favorable Outcome After 5-year Follow-up. American Journal of Surgical Pathology, 2009, 33, 1778-1782.	3.7	110
159	Interobserver Variation in the Histopathologic Reporting of Key Prognostic Parameters, Particularly Clark Level, Affects Pathologic Staging of Primary Cutaneous Melanoma. Annals of Surgery, 2009, 249, 641-647.	4.2	45
160	Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 2009, 33, 1386-1395.	3.7	95
161	Blue Nevi and Related Lesions. Advances in Anatomic Pathology, 2009, 16, 365-382.	4.3	141
162	Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology, 2009, 41, 383-387.	0.6	92

#	Article	IF	Citations
163	Desmoplastic neurotropic melanoma. Cancer, 2008, 113, 2770-2778.	4.1	131
164	Diagnostic Accuracy of Fine Needle Biopsy for Metastatic Melanoma and Its Implications for Patient Management. Annals of Surgical Oncology, 2008, 15, 323-332.	1.5	28
165	Sentinel Lymph Node Biopsy in Histologically Ambiguous Melanocytic Tumors With Spitzoid Features (So-Called Atypical Spitzoid Tumors). Annals of Surgical Oncology, 2008, 15, 302-309.	1.5	116
166	Confirmation of Sentinel Lymph Node Identity by Analysis of Fine-Needle Biopsy Samples Using Inductively Coupled Plasmaâ€“Mass Spectrometry. Annals of Surgical Oncology, 2008, 15, 934-940.	1.5	8
167	DIAGNOSIS AND MANAGEMENT OF SEBACEOUS CARCINOMA: AN AUSTRALIAN EXPERIENCE. ANZ Journal of Surgery, 2008, 78, 158-163.	0.7	49
168	Osteolysis in Third-Generation Alumina Ceramic-on-Ceramic Hip Bearings With Severe Impingement and Titanium Metallosis. Journal of Arthroplasty, 2008, 23, 1240.e13-1240.e19.	3.1	60
169	The detection and significance of melanoma micrometastases in sentinel nodes. Surgical Oncology, 2008, 17, 165-174.	1.6	48
170	Pathologic examination of sentinel lymph nodes from melanoma patients. Seminars in Diagnostic Pathology, 2008, 25, 100-111.	1.5	102
171	Fine-needle biopsy as a diagnostic technique for metastatic melanoma. Expert Opinion on Medical Diagnostics, 2008, 2, 1-10.	1.6	5
172	Cytologic Features of Metastatic and Recurrent Melanoma in Patients with Primary Cutaneous Desmoplastic Melanoma. American Journal of Clinical Pathology, 2008, 130, 715-723.	0.7	24
173	Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment. Future Oncology, 2008, 4, 535-551.	2.4	20
174	The Prognostic Significance of Isolated Immunohistochemically Positive Cells in Sentinel Lymph Nodes of Melanoma Patients. American Journal of Surgical Pathology, 2008, 32, 1106-1107.	3.7	11
175	Merkel cell carcinoma with fibrosarcomatous differentiation. Pathology, 2008, 40, 314-316.	0.6	20
176	Clinical relevance of melanoma micrometastases in sentinel nodes: too early to tell. Annals of Oncology, 2007, 18, 806-808.	1.2	17
177	Diagnosis of Metastatic Melanoma by Fine-Needle Biopsy. American Journal of Clinical Pathology, 2007, 127, 385-397.	0.7	72
178	Fine Needle Aspiration Cytology. Pathology, 2007, 39, 191.	0.6	0
179	Primary calvarial meningioma. Journal of Clinical Neuroscience, 2007, 14, 1235-1239.	1.5	30
180	Melanocytic nevus with focal atypical epithelioid components (clonal nevus) is a combined nevus. Journal of the American Academy of Dermatology, 2007, 56, 889-890.	1.2	16

#	Article	IF	Citations
181	Subcutaneous dermatofibrosarcoma protuberans in skin of the breast: may mimic a primary breast lesion. Pathology, 2007, 39, 446-448.	0.6	21
182	A 57-YEAR-OLD MAN WITH A DURAL-BASED PARIETAL LOBE TUMOR. Brain Pathology, 2007, 17, 460-463.	4.1	11
183	Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor. Clinical and Experimental Ophthalmology, 2007, 35, 275-280.	2.6	22
184	Mucinous cyst exhibiting severe dysplasia in gastric heterotopic pancreas associated withe gastrointestinal stromal tumour. World Journal of Gastroenterology, 2007, 13, 5781.	3.3	9
185	TACI mutation with invasive polyclonal CD8+ T-cell lymphoproliferation in a patient with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2006, 117, 870-877.	2.9	11
186	Histiocytoid Change in Breast Carcinoma. Acta Cytologica, 2006, 50, 548-552.	1.3	15
187	Clear cell atypical fibroxanthoma - report of a case with review of the literature. Journal of Cutaneous Pathology, 2006, 33, 343-348.	1.3	49
188	Metaplastic Ossification in Mammary Fibroadenoma. Breast Journal, 2006, 12, 276-277.	1.0	6
189	Endocrine mucin-producing sweat gland carcinoma: report of a case and review of the literature. Journal of Cutaneous Pathology, 2006, 33, 812-816.	1.3	60
190	Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology, 2006, 49, 523-532.	2.9	20
191	Florid (Floral) Synovitis. International Journal of Surgical Pathology, 2006, 14, 146-146.	0.8	0
192	Carcinoid Tumors of the Urinary Tract and Prostate. Archives of Pathology and Laboratory Medicine, 2006, 130, 1693-1706.	2.5	77
193	CD10 Immunohistochemical Staining in Urothelial Neoplasms. American Journal of Clinical Pathology, 2005, 124, 371-379.	0.7	26
194	CD10 Immunohistochemical Staining in Urothelial Neoplasms. American Journal of Clinical Pathology, 2005, 124, 371-379.	0.7	16
195	An Asymptomatic, Incidentally Discovered Pulmonary Tumor in a 41-Year-Old Woman. Archives of Pathology and Laboratory Medicine, 2005, 129, e191-e194.	2.5	3